SOURCE: Medistem Inc.

August 12, 2008 15:28 ET

Medistem Inc. Announces New Ticker Symbol Following Reverse Split and Name Change

Symbol Changed to MEDS.OB From MDSM.OB

PHOENIX, AZ--(Marketwire - August 12, 2008) - Medistem Inc. (OTCBB: MEDS) today announced a change in its corporate name and trading symbol.

Effective August 11, 2008, the Company changed its name from Medistem Laboratories, Inc. to Medistem Inc. to avoid confusion with respect to its business activities. The Company also effected a 1-for-25 reverse split of its common stock and, as required under NASDAQ OMX rules, was given a new ticker symbol. The new symbol is MEDS.OB.

"We see these events as being positive and necessary steps toward pursuing short and mid-term financing objectives," said Thomas Ichim, CEO of Medistem Inc. "Since our inception in 2005, we inherited a capital structure that had far too many shares outstanding for a Company of our size. Following this split, we have approximately 5.3 million shares outstanding which we believe is an appropriate capital structure for our organization."

About Medistem Inc.

Medistem Inc. is a biotechnology company founded to develop and commercialize technologies related to adult stem cell extraction, manipulation, and use for treating inflammatory and degenerative diseases. The company's lead product, the endometrial regenerative cell (ERC), is a "universal donor" stem cell derived from the menstrual blood that possesses the ability to differentiate into nine tissue types, produce large quantities of growth factors, and a large proliferative capacity. A peer reviewed publication describing this novel cell type may be found at The company is currently focusing on use of endometrial regenerative cells for treatment of critical limb ischemia, an advanced form of peripheral artery disease that causes approximately 160,000 amputations per year.

Cautionary Statement

This press release does not constitute an offer to sell or a solicitation of an offer to buy any of our securities. This press release may contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking information.

Factors which may cause actual results to differ from our forward-looking statements are discussed in our Form 10-K for the year ended December 31, 2007 as filed with the Securities and Exchange Commission.

Contact Information

  • For further information on Medistem Inc., please visit
    or contact:

    Thomas Ichim, PhD
    9255 Towne Center Drive
    Suite 450
    San Diego,CA 92122